#15
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
If you buy CBD from a local shop or order it online, both of those options could vanish—the ban would shut down hemp retail stores and eliminate all mail-order hemp sales.
Detailed legal analysis projects that standalone CBD/hemp stores, smoke shops, convenience stores, and gas stations that depend on intoxicating hemp products face severe disruption, probable closure, or forced pivots. All mail-order and interstate commerce in intoxicating hemp products will likely be eliminated. In adult-use states like NJ, licensed cannabis operators may see increased demand as consumers shift from unregulated hemp to dispensaries. Application of IRS Code § 280E upon reclassification could devastate remaining operators.
“Standalone CBD shops and hemp retailers are facing extinction, and the small business owners who built this industry from nothing deserve far better than a legislative death sentence.”
DELTA-8 IS DEAD. WHAT REPLACES IT?
The November ban definitively ends the legal gray area for delta-8 THC and other artificially derived cannabinoids. But the demand that built the delta-8 market hasn’t disappeared.
Delta-8 grew into a multi-billion dollar segment precisely because it filled a gap: consumers in states without legal marijuana wanted accessible, affordable, intoxicating cannabinoid products. The 2018 Farm Bill’s 0.3% delta-9 THC limit inadvertently created a loophole that the market exploited with remarkable speed.
So what happens to that demand after November? Three scenarios:
1. State cannabis programs absorb it. This is the policy-preferred outcome, but it requires states to dramatically expand access, reduce costs, and welcome consumers who were never in the traditional cannabis market.
2. The illicit market captures it. This is the most likely outcome in states without legal cannabis. When you ban a product people want without providing a legal alternative, black markets fill the void. We’ve seen this movie before.
3. A new compliant category emerges. Some companies are already pivoting to naturally occurring minor cannabinoids—THCV, CBN, CBG—that may fall outside the ban’s scope if derived from compliant hemp. Whether regulators allow this remains to be seen.
The honest answer is probably all three, in different proportions across different states. The delta-8 era is ending. The demand era isn’t.
Have thoughts on this? Share it:
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →